As of November 8, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of ProQR Therapeutics NV. The largest reported stake is ELI LILLY & Co's, at 15.6%. 12 filings are on record since August 12, 2025 (Schedule 13G/A, July 24, 2026).
Who owns ProQR Therapeutics N.V.?
Sell to companies like ProQR Therapeutics NV? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Van Herk Investments B.V. · Sole voting: 15,384,250 · Shared voting: 0 · Sole dispositive: 15,384,250 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-29
- · Reporting person: Aberdeen Group plc · Sole voting: 0 · Shared voting: 8,932,507 · Sole dispositive: 0 · Shared dispositive: 8,932,507 · SCHEDULE 13G, 2026-07-29
- · Reporting person: ELI LILLY & Co · Sole voting: 21,995,880 · Shared voting: 0 · Sole dispositive: 21,995,880 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-24
- · Holder: Patrick Johan Hendrik Krol · Percent: 5.2% · Shares: 5,528,862 · SCHEDULE 13G/A
- · Holder: Van Herk Investments B.V. · Percent: 10.9% · SCHEDULE 13D/A
ProQR Therapeutics NV has 12 Schedule 13D or 13G filings on record since 2025-08-12. 5 holders' latest filing reports 5% or more of ordinary shares, nominal value eur0.04 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ELI LILLY & Co | 15.6% | 21,995,880 | SCHEDULE 13G/A, 2026-07-24 | 2026-06-26 |
| Van Herk Investments B.V. | 10.9% | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 | 2026-07-27 |
| Aberdeen Group plc | 6.33% | 8,932,507 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Adage Capital Management, L.P. | 6.27% | 6,601,938 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| 5.2% | 5,528,862 | SCHEDULE 13G/A, 2026-07-15 | 2026-07-15 |
Holding shares or following this stake? See who's behind ProQR Therapeutics NV and the warning signs.
Free to see. No signup.
Keep reading
More on ProQR Therapeutics NV and the records around it.
ProQR Therapeutics NV elsewhere on the record
Companies that share a holder
- ELI LILLY & Co also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), Ionetix Corp / DE / (Jul 2026)
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Watch ProQR Therapeutics NV
Get an email when ProQR Therapeutics NV files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ProQR Therapeutics NV?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ProQR Therapeutics NV: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ProQR Therapeutics NV covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ELI LILLY & Co | 21,995,880 | 0 | 21,995,880 | 0 | SCHEDULE 13G/A, 2026-07-24 |
| Van Herk Investments B.V. | 15,384,250 | 0 | 15,384,250 | 0 | SCHEDULE 13D/A, 2026-07-29 |
| Van Herk Investments THI B.V. | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Van Herk Private Equity Investments B.V. | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Stichting Administratiekantoor Penulata | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Van Herk Management Services B.V. | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V. | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| A. van Herk Holding B.V. | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Stichting Administratiekantoor Abchrys | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Adrianus van Herk | 0 | 15,384,250 | 0 | 15,384,250 | SCHEDULE 13D/A, 2026-07-29 |
| Aberdeen Group plc | 0 | 8,932,507 | 0 | 8,932,507 | SCHEDULE 13G, 2026-07-29 |
| abrdn Inc. | 0 | 8,932,507 | 0 | 8,932,507 | SCHEDULE 13G, 2026-07-29 |
| Stichting Aescap Life Sciences | 4,156,878 | 0 | 4,156,878 | 0 | SCHEDULE 13G/A, 2026-07-15 |
| Privium Fund Management B.V. | 5,467,149 | 0 | 5,467,149 | 0 | SCHEDULE 13G/A, 2026-07-15 |
| Stichting Aescap Genetics | 1,310,271 | 0 | 1,310,271 | 0 | SCHEDULE 13G/A, 2026-07-15 |
| Inspirational Visions B.V. | 35,411 | 0 | 35,411 | 0 | SCHEDULE 13G/A, 2026-07-15 |
| Patrick Johan Hendrik Krol | 5,528,862 | 0 | 5,528,862 | 0 | SCHEDULE 13G/A, 2026-07-15 |
The latest filing identifies ProQR Therapeutics NV by CUSIP N71542109 and gives its principal executive office as Zernikedreef 9, Leiden (SCHEDULE 13D/A, 2026-07-29).
Purpose of Transaction (Item 4)
Van Herk Investments B.V.
Item 4 of the Schedule 13D is amended by adding the following: On July 27, 2026, the Reporting Persons filed a petition (the "Petition") with the Enterprise Chamber (Ondernemingskamer) of the Amsterdam Court of Appeal against the Issuer, pursuant to Article 2:345 of the Dutch Civil Code and including a request for immediate relief measures pursuant to Article 2:349a(2) of the Dutch Civil Code. The Petition requests that the Enterprise Chamber (i) order an investigation into the policies and conduct of affairs of the Issuer from May 22, 2024 to the present, based on alleged systematic deviations by the Issuer's board of directors from the Issuer's own governance framework and applicable governance standards, including with respect to the reappointment of certain directors, the composition and independence of the board and its committees, and director compensation, and (ii) as an immediate relief measure, appoint an independent non-executive director to the Issuer's board of directors pending the outcome of the investigation. The foregoing description of the Petition does not purport to be complete and is qualified in its entirety by reference to the full text of the English translation of the Petition, which is filed as Exhibit 99.2 hereto and incorporated herein by reference. The Reporting Persons reserve all rights to pursue any and all available legal remedies against the Issuer, members of the board of directors and/or certain officers of the Issuer, and continue to …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-29; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 6.27% | SCHEDULE 13G/A |
| 2025-08-20 | Van Herk Investments B.V. | 11.6% | SCHEDULE 13D/A |
| 2025-09-04 | Van Herk Investments B.V. | 12.6% | SCHEDULE 13D/A |
| 2025-09-30 | Van Herk Investments B.V. | 13.6% | SCHEDULE 13D/A |
| 2026-01-20 | Privium Fund Management B.V. | 5.2% | SCHEDULE 13G |
| 2026-02-06 | Van Herk Investments B.V. | 14.6% | SCHEDULE 13D/A |
| 2026-06-03 | Van Herk Investments B.V. | 14.6% | SCHEDULE 13D/A |
| 2026-06-30 | Van Herk Investments B.V. | 10.9% | SCHEDULE 13D/A |
| 2026-07-15 | Patrick Johan Hendrik Krol | 5.2% | SCHEDULE 13G/A |
| 2026-07-24 | ELI LILLY & Co | 15.6% | SCHEDULE 13G/A |
| 2026-07-29 | Van Herk Investments B.V. | 10.9% | SCHEDULE 13D/A |
| 2026-07-29 | Aberdeen Group plc | 6.33% | SCHEDULE 13G |
Questions about who owns ProQR Therapeutics NV
Who owns ProQR Therapeutics NV?
On this page, 5 holders' latest ownership filings report 5% or more of ProQR Therapeutics NV: ELI LILLY & Co (15.6%, Schedule 13G/A, filed 2026-07-24), Van Herk Investments B.V. (10.9%, Schedule 13D/A, filed 2026-07-29), Aberdeen Group plc (6.33%, Schedule 13G, filed 2026-07-29), Adage Capital Management, L.P. (6.27%, Schedule 13G/A, filed 2025-08-12) and Patrick Johan Hendrik Krol (5.2%, Schedule 13G/A, filed 2026-07-15).
Who are the largest shareholders of ProQR Therapeutics NV?
By the share each holder's latest filing reports, the largest holders of ProQR Therapeutics NV on this page are ELI LILLY & Co (15.6%), Van Herk Investments B.V. (10.9%) and Aberdeen Group plc (6.33%).
When did ELI LILLY & Co buy into ProQR Therapeutics NV?
The filings give report dates, not purchase dates. The earliest filing from ELI LILLY & Co on this page is the Schedule 13G/A, filed 2026-07-24, reporting 15.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for ProQR Therapeutics NV. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.